FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Julie Selkirk

Research Profile

Living Beings

Cricetinae

Anatomy

CHO Cells

Chemicals & Drugs

Physiology

Transfection

Procedures

Radioligand Assay

Co-author Network

Publications

TOP 3
Julie V Selkirk; R A John Challiss; Andrew Rhodes; R A Jeffrey McIlhinney
Characterization of an N-terminal secreted domain of the type-1 human metabotropic glutamate receptor produced by a mammalian cell line.
Mark S Nash; Julie V Selkirk; C E Gaymer; R A John Challiss; Stefan R Nahorski
Enhanced inducible mGlu1alpha receptor expression in Chinese hamster ovary cells.
Julie V Selkirk; Gary W Price; Stefan R Nahorski; R A John Challiss
Cell type-specific differences in the coupling of recombinant mGlu1alpha receptors to endogenous G protein sub-populations.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Julie Selkirk (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2002: Julie V Selkirk; R A John Challiss; Andrew Rhodes; R A Jeffrey McIlhinney
Characterization of an N-terminal secreted domain of the type-1 human metabotropic glutamate receptor produced by a mammalian cell line.
Journal of neurochemistry 2002;80(2):346-53.
2001: Mark S Nash; Julie V Selkirk; C E Gaymer; R A John Challiss; Stefan R Nahorski
Enhanced inducible mGlu1alpha receptor expression in Chinese hamster ovary cells.
Journal of neurochemistry 2001;77(6):1664-7.
2001: Julie V Selkirk; Gary W Price; Stefan R Nahorski; R A John Challiss
Cell type-specific differences in the coupling of recombinant mGlu1alpha receptors to endogenous G protein sub-populations.
Neuropharmacology 2001;40(5):645-56.
2000: E Hermans; R Saunders; Julie V Selkirk; Rajendra Mistry; Stefan R Nahorski; R A John Challiss
Complex involvement of pertussis toxin-sensitive G proteins in the regulation of type 1alpha metabotropic glutamate receptor signaling in baby hamster kidney cells.
Molecular pharmacology 2000;58(2):352-60.
2000: Jeannette Watson; LJ Collin; M Ho; Graham Riley; Claire Scott; Julie V Selkirk; Gary W Price
5-HT(1A) receptor agonist-antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems.
British journal of pharmacology 2000;130(5):1108-14.
1999: Derek N Middlemiss; Manfred Göthert; Eberhard Schlicker; Claire M Scott; Julie V Selkirk; Jeannette Watson; Laramie M Gaster; Paul A Wyman; Graham Riley; Gary W Price
SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor.
European journal of pharmacology 1999;375(1-3):359-65.
1998: Laramie M Gaster; P Ham; GF Joiner; Frank D King; KR Mulholland; Paul A Wyman; James Hagan; Gary W Price; Claire Roberts; Carol Routledge; Julie V Selkirk; P D Slade; Derek N Middlemiss
The selective 5-HT1B receptor inverse agonist SB-224289, potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.
Annals of the New York Academy of Sciences 1998;861():270-1.
1998: Julie V Selkirk; Claire Scott; M Ho; M J Burton; Jeannette Watson; Laramie M Gaster; LJ Collin; BJ Jones; Derek N Middlemiss; Gary W Price
SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity.
British journal of pharmacology 1998;125(1):202-8.
1998: Laramie M Gaster; Frank E Blaney; S Davies; DM Duckworth; P Ham; S Jenkins; AJ Jennings; GF Joiner; Frank D King; KR Mulholland; Paul A Wyman; James Hagan; Jonathan P Hatcher; BJ Jones; Derek N Middlemiss; Gary W Price; Graham Riley; Claire Roberts; Carol Routledge; Julie V Selkirk; P D Slade
The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.
Journal of medicinal chemistry 1998;41(8):1218-35.